


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-34 (Canceled)

35. (Previously Presented) A chemical compound of formula (I):



wherein:

R₁ to R₃ are independently selected from hydrogen and lower alkyl;

X₁ is selected from N and C-R₄;

X₂ is selected from N and C-R₅;

X₃ is selected from N and C-R₆;

X₄ is selected from N and C-R₇;

wherein only one of X₁ to X₄ is N;

R₄, R₅ and R₇ are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkoyl, aryloyl, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino, nitro, cyano, carboalkoxy, carboaryloxy and carboxy; and

R₆ is selected from hydrogen, halogen, alkyl, aryl, aryloxy, alkylthio, arylthio, alkylsulfoxyl, arylsulfoxyl, alkylsulfonyl, arylsulfonyl, amino, alkylamino, dialkylamino and cyano;

with the proviso that R₄ to R₇ are not all selected as hydrogen,
or a pharmaceutically acceptable salt or addition compound thereof.

36. (Previously Presented) A compound according to claim 35, wherein R₁ is selected from hydrogen and methyl.

37. (Previously Presented) A compound according to claim 35, wherein R₂ is hydrogen.

38. (Previously Presented) A compound according to claim 35, wherein R₃ is selected from hydrogen and methyl.

39. (Previously Presented) A compound according to claim 35, wherein X₂ is C-R₅.

40. (Previously Presented) A compound according to claim 35, wherein X₃ is C-R₆.

41. (Previously Presented) A compound according to claim 35, wherein X₄ is C-R₇.

42. (Previously Presented) A compound according to claim 35, wherein X₁ is C-R₄.

43. (Previously Presented) A compound according to claim 35, wherein two of R₄, R₅, R₆ and R₇ are hydrogen.

44. (Previously Presented) A compound according to claim 43, wherein R₄ and R₆ are hydrogen.

45. (Previously Presented) A compound according to claim 35, wherein two of R₄, R₅, R₆ and R₇ are independently selected from hydrogen, chlorine, fluorine, trifluoromethyl and bromine.

46. (Previously Presented) A compound according to claim 35, wherein three of R₄, R₅, R₆ and R₇ are hydrogen.

47. (Previously Presented) A compound according to claim 46, wherein R₄, R₆ and R₇ are hydrogen.

48. (Previously Presented) A compound according to claim 35, wherein R₄ is hydrogen.

49. (Previously Presented) A compound according to claim 35, wherein R₅ is halogen.

50. (Previously Presented) A compound according to claim 35, wherein R₆ is hydrogen.

51. (Previously Presented) A compound according to claim 35, wherein R₇ is halogen.

52. (Previously Presented) A compound according to claim 35, wherein the compound is:

(RS) 7-Chloro-1,2,3,4,10,10a-hexahydro-6-aza-pyrazino[1,2-a]indole furmarate.

53-58. (Canceled)


59. (Currently Amended) A method of treatment of ~~according to claim 53,~~ wherein said disorder is obesity comprising administering to a patient in need of such treatment an effective dose of a compound of formula (I) as set out in claim 35.

60. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) as set out in claim 35 in combination with a pharmaceutically acceptable carrier or excipient.

61. (Previously Presented) A method of making a pharmaceutical composition comprising combining a compound of formula (I) as set out in claim 35 with a pharmaceutically acceptable carrier or excipient.

62. (Previously Presented) A process for the preparation of a compound of formula (I) according to claim 35, said process comprising the steps of:

(i) treating a compound of formula (IX) with an aldehyde of formula RCHO and then exposing the compound to acid to obtain a compound of formula (X), wherein X_1 , X_2 , X_3 , X_4 , R_2 and R_3 are as described in claim 35, and



(ii) reduction of a compound of formula (X).